factory wholesale Semaglutide side chain(N-3segment) Semaglutide intermediates 1118767-16-0
TDS
86-39-5
Industrial Grade
99%
shenzhen
subi
5/10/15mg*10vials
2025-06-07
peptone
-
Product Description
-
Seller Information
-
DescriptionECHEMI Editorial ReferenceBeige powderCertificates
-
TDS
Basic Info-
Product Name:
2-Chlorothioxanthone
Other Name:9H-Thioxanthen-9-one,2-chloro-;Thioxanthen-9-one,2-chloro-;2-Chloro-9H-thioxanthen-9-one;2-Chlorothiaxanthone;2-Chlorothioxanthen-9-one;2-Chlorothioxanthone;Sandoray 1050;UCI 100;Kayacure CTX;Quantacure CTX;Nisso Cure CTX;Speedcure CTX;Kayacure DETA-S;CTX;Gencure CTX
CAS No.:86-39-5
Molecular Formula:C13H7ClOS
InChIKeys:InChIKey=ZCDADJXRUCOCJE-UHFFFAOYSA-N
Molecular Weight:246.71
Exact Mass:246.71
EC Number:201-667-2
UNII:RGS87T004B
HScode:2932999099
Categories:
Characteristics-
PSA:
42.4
XLogP3:4.6
Appearance:yellow powder
Density:1.53 g/cm3
Melting Point:174 °C
Boiling Point:409.4ºC at 760 mmHg
Flash Point:196 °F
Refractive Index:1.696
Water Solubility:Partly miscible in water.
Research-
Class:
GLP-1R agonist
Status:FDA-approved (Ozempic / Wegovy / Rybelsus)
Mechanism:Long-acting, selective glucagon-like peptide-1 (GLP-1) receptor agonist with 94% sequence homology to human GLP-1. Engineered for extended half-life (~1 week) via albumin binding (fatty acid acylation at Lys26) and resistance to DPP-4 degradation (Aib substitution at position 8). Promotes insulin secretion, inhibits glucagon release, delays gastric emptying, and reduces appetite via central nervous system GLP-1R activation.
Activity note:Potent, selective GLP-1R agonist. Reported binding affinity Ki = 0.38 ± 0.06 nM. Semaglutide is a human GLP-1 analog with structural modifications for albumin binding (C18 fatty diacid at Lys26) and enzymatic stability (Aib8 substitution).
Source:Lau J, et al. J Med Chem. 2015;58(18):7370-7380. Wilding JPH, et al. N Engl J Med. 2021;384(11):989-1002.DOI
Clinical Development:FDA:Ozempic, Wegovy, Rybelsus (approved 2017-12-05)
References-
ChEMBL:DrugBank:KEGG DRUG:PubChem:Literature:
NEJM: Wilding et al. (2021) — STEP-1; NEJM: Marso et al. (2016) — SUSTAIN-6; J Med Chem: Lau et al. (2015) — Discovery of Semaglutide; FDA: Ozempic (NDA 209637)
Disclaimer:Semaglutide is approved as a prescription medicine (Ozempic, Wegovy, Rybelsus) in certain jurisdictions. This listing is for industrial and laboratory research use only. Research-chemical listings on B2B marketplaces are not interchangeable with approved medicines. Confirm CAS, specification, and regulatory pathway with the seller. It is not medical advice, a clinical recommendation, or an approved therapy description.
Hazard IdentificationClassification of the substance or mixture
Not classified.
GHS label elements, including precautionary statements
Pictogram(s) No symbol. Signal word No signal word
Hazard statement(s) none
Precautionary statement(s) Prevention none
Response none
Storage none
Disposal none
Other hazards which do not result in classification
no data available
Handling and StoragePrecautions for safe handling
Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.
Conditions for safe storage, including any incompatibilities
Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
peptone
-
Location:
Room A109, No. 29 Dongting Road, Hexi District, Tianjin
-
Payment Terms:
TT against copy of documents
-
Average lead Time:
3
-
Total Annual Revenue:
$2.5 million-$5 million
-
Total Employees:
Less than 5
-
Year of Establishment:
2024
-
-
Country Product Purchase Quantity Date Posted Post an enquiry for this product